Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4CNS 3Gynecologic 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Breast 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × gadobutrol × Genitourinary × Clear all
NCT04910425 2025-10-21

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Northwestern University

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03404648 2021-02-08

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

Mayo Clinic

Phase 3 Completed
19 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡